Neurofeedback training for alcohol dependence versus treatment as usual: study protocol for a randomized controlled trial

W Miles Cox, Leena Subramanian, David E J Linden, Michael Lührs, Rachel McNamara, Rebecca Playle, Kerenza Hood, Gareth Watson, Joseph R Whittaker, Raman Sakhuja, Niklas Ihssen, W Miles Cox, Leena Subramanian, David E J Linden, Michael Lührs, Rachel McNamara, Rebecca Playle, Kerenza Hood, Gareth Watson, Joseph R Whittaker, Raman Sakhuja, Niklas Ihssen

Abstract

Background: Real-time functional magnetic resonance imaging (rtfMRI) is used for neurofeedback training (NFT). Preliminary results suggest that it can help patients to control their symptoms. This study uses rtfMRI NFT for relapse prevention in alcohol dependence.

Methods/design: Participants are alcohol-dependent patients who have completed a detoxification programme within the past 6 months and have remained abstinent. Potential participants are screened for eligibility, and those who are eligible are randomly assigned to the treatment group (receiving rtfMRI NFT in addition to treatment as usual) or the control group (receiving only treatment as usual). Participants in both groups are administered baseline assessments to measure their alcohol consumption and severity of dependence and a variety of psychological and behavioural characteristics that are hypothesised to predict success with rtfMRI NFT. During the following 4 months, experimental participants are given six NFT sessions, and before and after each session various alcohol-related measures are taken. Participants in the control group are given the same measures to coincide with their timing in the experimental group. Eight and 12 months after the baseline assessment, both groups are followed up with a battery of measures. The primary research questions are whether NFT can be used to teach participants to down-regulate their brain activation in the presence of alcohol stimuli or to up-regulate their brain activation in response to pictures related to healthy goal pursuits, and, if so, whether this translates into reductions in alcohol consumption. The primary outcome measures will be those derived from the functional brain imaging data. We are interested in improvements (i.e., reductions) in participants' alcohol consumption from pretreatment levels, as indicated by three continuous variables, not simply whether or not the person has remained abstinent. The indices of interest are percentage of days abstinent, drinks per drinking day, and percentage of days of heavy drinking. General linear models will be used to compare the NFT group and the control group on these measures.

Discussion: Relapse in alcohol dependence is a recurring problem, and the present evaluation of the role of rtfMRI in its treatment holds promise for identifying a way to prevent relapse.

Trial registration: ClinicalTrials.gov Identifier: NCT02486900 , registered on 26 June 2015.

Keywords: Alcohol dependence; Functional magnetic resonance imaging; Neurofeedback training; Randomised controlled trial; Relapse prevention.

Figures

Fig. 1
Fig. 1
Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the phases of the BRAINTRAIN trial
Fig. 2
Fig. 2
Illustration of the neurofeedback setup used in the intervention group. Participants receive real-time feedback about the computed activation level in target areas that have been identified in a preceding localiser scan as key components of the motivational network involved in alcohol-cue reactivity. Activation levels are represented as varying picture sizes, with decreasing picture sizes reflecting successful down-regulation

References

    1. Kamiya J. Operant control of the EEG alpha rhythm and some of its reported effects on consciousness. Biofeedback and self-control: an Aldine Reader on the regulation of bodily processes and consciousness. 1971.
    1. Linden DEJ. The brain controls itself: from brain reading to brain modulation via neurofeedback. In: Linden DEJ, editor. Brain control: developments in therapy and implications for society. New York: Palgrave Macmillan; 2014.
    1. De Bease C. Biofeedback Certification Institute of America certification: building skills without walls. Biofeedback. 2007;35:48–9.
    1. deCharms RC, Maeda F, Glover GH, Ludlow D, Pauly JM, Soneji D, Gabrieli JD, Mackey SC. Control over brain activation and pain learned by using real-time functional MRI. Proc Natl Acad Sci U S A. 2005;102(51):18626–31. doi: 10.1073/pnas.0505210102.
    1. Subramanian L, Hindle JV, Johnston S, Roberts MV, Husain M, Goebel R, Linden D. Real-time functional magnetic resonance imaging neurofeedback for treatment of Parkinson’s disease. J Neurosci. 2011;31(45):16309–17. doi: 10.1523/JNEUROSCI.3498-11.2011.
    1. Linden DEJ, Habes I, Johnston SJ, Linden S, Tatineni R, Subramanian L, Sorger B, Healy D, Goebel R. Real-time self-regulation of emotion networks in patients with depression. PLoS ONE. 2012;7(6):e38115.
    1. Li X, Hartwell KJ, Borckardt J, Prisciandaro JJ, Saladin ME, Morgan PS, Johnson KA, Lematty T, Brady KT, George MS. Volitional reduction of anterior cingulate cortex activity produces decreased cue craving in smoking cessation: a preliminary real-time fMRI study. Addict Biol. 2013;18(4):739–48. doi: 10.1111/j.1369-1600.2012.00449.x.
    1. Canterberry M, Hanlon CA, Hartwell KJ, Li X, Owens M, LeMatty T, Prisciandaro JJ, Borckardt J, Saladin ME, Brady KT, George MS. Sustained reduction of nicotine craving with real-time neurofeedback: exploring the role of severity of dependence. Nicotine Tob Res. 2013;15(12):2120–4. doi: 10.1093/ntr/ntt122.
    1. Hanlon CA, Hartwell KJ, Canterberry M, Li X, Owens M, LeMatty T, Prisciandaro JJ, Borckardt J, Brady KT, George MS. Reduction of cue-induced craving through realtime neurofeedback in nicotine users: the role of region of interest selection and multiple visits. Psychiatry Res. 2013;213(1):79–81. doi: 10.1016/j.pscychresns.2013.03.003.
    1. Karch S, Keeser D, Hümmer S, Paolini M, Kirsch V, Karali, T, Kupka M, Rauchmann B-S, Chrobok A, Blautzik J, Koller G, Ertl-Wagner B, Pogarell O. Modulation of craving related brain responses using real-time fMRI in patients with alcohol use disorder. PLoS ONE. 2015. .
    1. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC. The Mini International Neuropsychiatric Interview (MINI): a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12(5):224–31. doi: 10.1016/S0924-9338(97)83296-8.
    1. Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio: The Psychological Corporation; 1999.
    1. Sobell LC, Sobell MB. Timeline followback: A technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen J, editors. Measuring alcohol consumption: psychosocial and biological methods. Totowa: Humana Press; 1992. pp. 41–72.
    1. Ihssen N, Cox WM, Wiggett A, Fadardi JS, Linden EJ. Differentiating heavy from light drinkers by neural responses to visual alcohol cues and other motivational stimuli. Cereb Cortex. 2011;21:1408–15. doi: 10.1093/cercor/bhq220.
    1. Cox WM, Klinger E. A motivational model of alcohol use. J Abnorm Psychol. 1988;97:168–80. doi: 10.1037/0021-843X.97.2.168.
    1. Cox WM, Klinger E. A motivational model of alcohol use: determinants of use and change. In: Cox WM, Klinger E, editors. Handbook of motivational counseling: goal-based approaches to assessment and intervention with addiction and other problems. Chichester: Wiley-Blackwell; 2011.
    1. Cox WM, Klinger E, Fadardi JS. The motivational basis of cognitive determinants of addictive behaviors. Addict Behav. 2015;44:16–22. doi: 10.1016/j.addbeh.2014.11.019.
    1. Sokunbi MO, Linden DEJ, Habes I, Johnston SJ, Ihssen N. Real-time fMRI brain-computer interface: development of a “motivational feedback” subsystem for the regulation of visual cue reactivity. Front Behav Neurosci. 2014;8:1–10. doi: 10.3389/fnbeh.2014.00392.
    1. Agosti V, Nunes EV, O’Shea D. Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta‐analysis. Am J Addict. 2012;21(6):501–7. doi: 10.1111/j.1521-0391.2012.00270.x.
    1. Schuckit MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. 6. New York: Springer Science + Business Media; 2006.
    1. Institute of Medicine (US) Committee on Treatment of Alcohol Problems. Broadening the Base of Treatment for Alcohol Problems. Washington (DC): National Academies Press (US); 1990.
    1. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19(3):600–6. doi: 10.1111/j.1530-0277.1995.tb01554.x.
    1. Roberts JS, Anton RF, Latham PK, Moak DH. Factor structure and predictive validity of the obsessive compulsive drinking scale. Alcohol Clin Exp Res. 1999;23(9):1484–91. doi: 10.1111/j.1530-0277.1999.tb04671.x.
    1. Cox WM, Fadardi JS, Pothos EM. The addiction-Stroop test: theoretical considerations and procedural recommendations. Psychol Bull. 2006;132(3):443–76. doi: 10.1037/0033-2909.132.3.443.
    1. Stockwell T, Hodgson R, Edwards G, Taylor C, Rankin H. The development of a questionnaire to measure severity of alcohol dependence. Br J Addict. 1979;74(1):79–87. doi: 10.1111/j.1360-0443.1979.tb02415.x.
    1. Wells A, Davies MI. The Thought Control Questionnaire: a measure of individual differences in the control of unwanted thoughts. Behav Res Ther. 1994;32(8):871–8. doi: 10.1016/0005-7967(94)90168-6.
    1. Luciano JV, Algarabel S, Tomás JM, Martínez JL. Development and validation of the thought control ability questionnaire. Personal Individ Differ. 2005;38(5):997–1008. doi: 10.1016/j.paid.2004.06.020.
    1. Heuchert J, McNair D. Profile of mood states. 2. North Tonawanda: Multi-Health Systems, Inc.; 2012.
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Beck A, Steer R, Brown G. Manual for Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir